English  |  正體中文  |  简体中文  |  Items with full text/Total items : 6047/14565 (42%)
Visitors : 13679862      Online Users : 347
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.fy.edu.tw:8080/ir/handle/987654321/3925


    Title: Safety and immunoresponse study of intravesical instillation of Taipei-NIPM Bacillus Calmette-Guerin.
    Authors: Chang, S.Y.;Yu, D.S.;Ma, C.P.;Liau, M.Y.
    Contributors: 輔英科技大學 生物科技系
    Date: 1992-08-01
    Issue Date: 2010-10-08 10:54:42 (UTC+8)
    Abstract: The intravesical instillation of bacillus Calmette-Guérin (BCG) has proved to be an effective modality for prophylaxis of recurrent superficial bladder cancer and treatment of carcinoma in situ. The domestic BCG, named Taipei-NIPM, which is produced by the National Institute of Preventive Medicine, has been used as an anti-TBC vaccine in Taiwan for decades. In this study, we have investigated the safety and immune response in animals after intravesical BCG treatment to test its feasibility in future clinical application. Weekly instillation of BCG (1 mg/ml, 5-8 x 10(7) CFU/mg) for 6 instillations could induce lymphocytic infiltration, submucosal fibrosis, and granulomatous reaction after 4 weeks with mild decrease of bladder weight and high incidence of hematopyuria (75%). No changes in appetite, body weight, and splenic weight were noticed in the chronically treated rats. A delayed hypersensitivity test through foot pad swelling measurement reached 80% positive rates at 2 weeks. Cystometric study revealed a mild decrease in bladder capacity (33.3%) at 2 weeks and of contractile pressure of the urinary bladder in rats receiving BCG instillations. In addition, increase in lymphocytic infiltration by natural killer (NK) cells against YAC-1 cells could be detected after BCG treatment and this was related to dosage of BCG. The urothelial damage by cauterization and the number of instillations could also enhance NK cell activity. Low toxicity and high safety of intravesical instillation of the domestic BCG are demonstrated by this pilot animal study. This information on local and systemic immune responses can provide a solid base for future efficacy of BCG immunotherapy in bladder cancer patients using this domestic strain BCG.
    Relation: Eur Urol. 21(1):52-7.
    Appears in Collections:[生物科技系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML964View/Open


    All items in FYIR are protected by copyright, with all rights reserved.


    本網站典藏內容為學術研究目的之提供,請尊重著作權人之權益合理使用,請勿任意重製、轉貼、改作及散佈。

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback